{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T14:05:05Z","timestamp":1720965905582},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.bulcan.2018.09.008","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T01:22:39Z","timestamp":1547169759000},"page":"151-161","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Traitement des cancers colorectaux par immunoth\u00e9rapie\u00a0: aller au-del\u00e0 de MSI avec la classification mol\u00e9culaire (CMS) et la charge mutationnelle"],"prefix":"10.1016","volume":"106","author":[{"given":"Romain","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilien","family":"Heran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pudlarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Hilmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Tournigand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2018.09.008_bib0275","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0280","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0285","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1\u00a0blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0290","first-page":"9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in dna mismatch repair\u2013deficient\/microsatellite instability\u2013high metastatic colorectal cancer","volume":"76","author":"Overman","year":"2017","journal-title":"J Clin Oncol 2018: JCO"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0295","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2\u00a0study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0300","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1\u00a0blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0305","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Muzny","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0310","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0315","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13073-017-0434-0","article-title":"Multilevel genomics of colorectal cancers with microsatellite instability\u2014clinical impact of JAK1\u00a0mutations and consensus molecular subtype 1","volume":"9","author":"Sveen","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0320","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1158\/1078-0432.CCR-15-2879","article-title":"Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy","volume":"22","author":"Becht","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0325","doi-asserted-by":"crossref","first-page":"105299","DOI":"10.18632\/oncotarget.22169","article-title":"Immunological landscape of consensus clusters in colorectal cancer","volume":"8","author":"Karpinski","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0330","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.2017.35.15_suppl.3510","article-title":"Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial","volume":"35","author":"Stintzing","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0335","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2017.35.15_suppl.3511","article-title":"Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB\/SWOG 80405 (Alliance)","volume":"35","author":"Lenz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0340","doi-asserted-by":"crossref","first-page":"18698","DOI":"10.18632\/oncotarget.24617","article-title":"Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer","volume":"9","author":"Okita","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0345","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc.2016.126","article-title":"Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer","volume":"17","author":"Dienstmann","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0350","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/1078-0432.CCR-17-1090","article-title":"KRAS mutation and consensus molecular subtypes 2\u00a0and 3\u00a0are independently associated with reduced immune infiltration and reactivity in colorectal cancer","volume":"24","author":"Lal","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0355","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-0032","article-title":"Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer","volume":"22","author":"Dunne","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"95","key":"10.1016\/j.bulcan.2018.09.008_bib0360","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejca.2018.01.087","article-title":"Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice","volume":"1990","author":"Tachon","year":"2018","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0365","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2015.65.1067","article-title":"Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels","volume":"34","author":"Stadler","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0370","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite instability status determined by next generation sequencing and compared with PD L1\u00a0and tumor mutational burden in 11,348\u00a0patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0375","doi-asserted-by":"crossref","first-page":"68638","DOI":"10.18632\/oncotarget.11862","article-title":"The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy","volume":"7","author":"Ahn","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0380","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc.2015.12","article-title":"A panoply of errors: polymerase proofreading domain mutations in cancer","volume":"16","author":"Rayner","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0385","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2468-1253(16)30014-0","article-title":"Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study","volume":"1","author":"Domingo","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0390","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","article-title":"Comprehensive analysis of hypermutation in human cancer","volume":"171","author":"Campbell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0395","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2017.03.027","article-title":"Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency","volume":"113","author":"Bourdais","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0400","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/cam4.1245","article-title":"POLE somatic mutations in advanced colorectal cancer","volume":"6","author":"Guerra","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0405","doi-asserted-by":"crossref","first-page":"142","DOI":"10.6004\/jnccn.2017.0016","article-title":"Response to PD-1\u00a0blockade in microsatellite stable metastatic colorectal cancer harboring a pole mutation","volume":"15","author":"Gong","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0410","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-1031","article-title":"Regression of chemotherapy-resistant polymerase \u025b (POLE) ultra-mutated and MSH6\u00a0hyper-mutated endometrial tumors with nivolumab","author":"Santin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0415","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1634\/theoncologist.2017-0342","article-title":"Tumor mutational burden guides therapy in a treatment refractory POLE-mutant uterine carcinosarcoma","volume":"23","author":"Bhangoo","year":"2018","journal-title":"The Oncologist"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0420","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4496","article-title":"DKK2\u00a0imparts tumor immunity evasion through \u03b2-catenin-independent suppression of cytotoxic immune-cell activation","volume":"24","author":"Xiao","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0425","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-017-0471-6","article-title":"Wnt\/beta-catenin pathway: modulating anticancer immune response","volume":"10","author":"Pai","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0430","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jtho.2017.04.017","article-title":"Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1\u00a0blockade","volume":"12","author":"Akbay","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0435","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the intersections between metabolism and cancer biology","volume":"168","author":"Vander Heiden","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0440","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0445","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0450","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/eji.200939887","article-title":"VEGFR2\u00a0is selectively expressed by FOXP3high CD4+ Treg","volume":"40","author":"Suzuki","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0455","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0460","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000320609","article-title":"Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer","volume":"79","author":"Manzoni","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0465","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0470","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1158\/0008-5472.CAN-17-2006","article-title":"In Silico modeling of immunotherapy and stroma-targeting therapies in human colorectal cancer","volume":"77","author":"Kather","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0475","series-title":"SCIENTIFIC COMMITTEE CHAIR.pdf n.d","author":"Melnick","year":"2018"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0480","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0485","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13059-015-0620-6","article-title":"Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy","volume":"16","author":"Angelova","year":"2015","journal-title":"Genome Biol"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0490","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0495","doi-asserted-by":"crossref","first-page":"xii3","DOI":"10.1093\/annonc\/mdx544","article-title":"Novel tools to assist neoepitope targeting in personalized cancer immunotherapy","volume":"28","author":"Saini","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0500","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP kinase inhibition promotes T Cell and anti-tumor activity in combination with PD-L1\u00a0checkpoint blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0505","unstructured":"Johanna C, Bendell, Yung-Jue Bang, Cheng Ean Chee, et al. A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC). https:\/\/meetinglibrary.asco.org\/record\/155749\/abstract. (accessed July 27, 2018)"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0510","unstructured":"World_GI_Abstract_Titles_and_Authors.pdf n.d"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0515","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0520","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0525","doi-asserted-by":"crossref","first-page":"81778","DOI":"10.18632\/oncotarget.13207","article-title":"Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer","volume":"7","author":"Kwak","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0530","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0535","first-page":"110 (1)","article-title":"The balance between cytotoxic t-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors","author":"Marisa","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2018.09.008_bib0270","first-page":"18","article-title":"Immunogenomic classification of colorectal cancer and therapeutic implications","author":"Roelands","year":"2017","journal-title":"Int J Mol Sci"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118303345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118303345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T07:25:32Z","timestamp":1606029932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118303345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0007455118303345"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.09.008","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement des cancers colorectaux par immunoth\u00e9rapie\u00a0: aller au-del\u00e0 de MSI avec la classification mol\u00e9culaire (CMS) et la charge mutationnelle","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}